Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.
Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
J Arthroplasty. 2023 May;38(5):909-913. doi: 10.1016/j.arth.2022.12.006. Epub 2022 Dec 8.
Recent evidence has suggested a benefit to extended postoperative prophylactic oral antibiotics after two-stage exchange arthroplasty for treatment of periprosthetic joint infections. We sought to determine reinfection rates with and without a short course of oral antibiotics after two-stage exchange procedures.
A retrospective review identified patients undergoing two-stage exchange arthroplasty for periprosthetic joint infection of the hip or knee. Patients were excluded if they failed a prior two-stage exchange, had positive cultures at reimplantation, prolonged intravenous antibiotics postoperatively, and/or life-long suppression. This resulted in 444 reimplantations (210 hips and 234 knees). Patients were divided into three cohorts based on the duration of oral antibiotics after reimplantation: no antibiotics (102), ≤2 weeks (266), or >2 weeks (76). The primary endpoint was reinfection within 1 year of reimplantation.
Within 1 year of reimplantation, there were 34 reinfections. In the no-antibiotic, ≤ 2-week, and >2-week cohorts the reinfection rates were 14.1, 7.0, and 6.4%, respectively. Multivariate Cox regression showed a reduced reinfection rate in the ≤2-week cohort relative to no antibiotics (hazard ratio [HR]: 0.38, P = .01). While the smaller cohort with >2 weeks of antibiotics did not significantly reduce the reinfection rate (HR: 0.41, P = .12), when combined with the ≤2-week cohort, use of oral antibiotics had an overall reduction of the reinfection rate (HR: 0.39, P = .01).
These data support the hypothesis that a short course of oral antibiotics after reimplantation decreases the 1-year reinfection rate. Future randomized studies should seek to examine the efficacy of different durations of oral antibiotics to reduce reinfection.
Prognostic Level IV.
最近的证据表明,在两阶段髋关节或膝关节置换术治疗人工关节感染后,延长术后预防性口服抗生素的疗程有益。我们旨在确定两阶段手术后短期口服抗生素与不使用抗生素的再感染率。
回顾性研究确定了接受两阶段髋关节或膝关节置换术治疗人工关节感染的患者。如果患者在两阶段之前失败、再植入时培养阳性、术后静脉注射抗生素时间延长和/或长期使用抗生素,则将其排除在外。最终纳入 444 例(210 髋和 234 膝)。根据再植入后口服抗生素的持续时间,患者分为三组:无抗生素(102 例)、≤2 周(266 例)或>2 周(76 例)。主要终点是再植入后 1 年内的再感染。
在再植入后 1 年内,有 34 例再感染。在无抗生素、≤2 周和>2 周组中,再感染率分别为 14.1%、7.0%和 6.4%。多变量 Cox 回归显示,在≤2 周组中,再感染率相对于无抗生素组降低(风险比[HR]:0.38,P=.01)。尽管抗生素使用时间>2 周的较小队列并未显著降低再感染率(HR:0.41,P=.12),但当与≤2 周组相结合时,口服抗生素的总体再感染率降低(HR:0.39,P=.01)。
这些数据支持以下假设,即再植入后短期口服抗生素可降低 1 年的再感染率。未来的随机研究应着眼于检查不同时间长度的口服抗生素对降低再感染的疗效。
预测 IV 级。